Kadcyla (ado-trastuzumab emtansine)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 USE IN SPECIFIC POPULATIONS Hepatic Impairment (revised) No adjustment to the starting dose is required for patients...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts